www.dailypolitical.com ·
Davita Nysedva Releases Fy 2026 Earnings Guidance
Topic context
This topic has been covered 269175 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedDaVita, a US-based kidney dialysis provider, reported Q1 earnings beat and issued FY2026 guidance slightly above consensus. The commercial mechanism is company-specific: higher revenue and EPS signal potential margin expansion or volume growth in dialysis services. No direct commodity, supply chain, or macro channel identified. Impact is single-company/supply-chain-specific.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- DaVita FY2026 EPS guidance: $14.10-$15.20, consensus $14.13
- Q1 2026 EPS $2.87 vs estimate $2.33
- Q1 revenue $3.42B vs estimate $3.36B
- Stock rose $2.08 to $195.96, market cap $12.58B
- Analyst ratings: 2 Buy, 5 Hold, 1 Sell, avg target $180
DaVita's Q1 earnings beat and guidance raise lead to flat sentiment for dialysis services in the short term.
Sign in to see all sector verdicts, full thesis and counter-argument debate.
Sector impact at a glance
- GLOBAL_HEALTHCAREshort
Related stories
finance.yahoo.com
Ncmi Q1 2026 Earnings Transcript
finance.yahoo.com
Transcript Valneva Q1 2026 Earnings
finance.yahoo.com
Aytu Aytu Q3 2026 Earnings
economictimes.indiatimes.com
IPO Investors Brace for 73 Lock in Expiries Worth 34 Billion in Three Months Will Your Portfolio Be Impacted
fool.com